CSPC Pharmaceutical Group Gains NMPA Approval for Bivalent COVID-19 mRNA Vaccine Study
CSPC Pharmaceutical Group Ltd (HKG: 1093), a prominent pharmaceutical company based in China, has announced...
Clinical trial approval / initiation
Alphamab Oncology and 3D Medicines Gain FDA Approval for Envafolimab Phase III Trial
Partners Alphamab Oncology (HKG: 9966) and 3D Medicines (HKG: 1244) have announced that they have...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
TG ImmunoPharma’s Bispecific Antibody TGI-6 Approved for Phase I Clinical Study by NMPA
China-based TG ImmunoPharma Co., Ltd has announced that it has received approval from the National...
Abbisko Therapeutics Gets NMPA Approval for Phase I Study of ABSK112 in NSCLC
Shanghai-based biotechnology firm Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...
Zhejiang Jianfeng Receives FDA Approval for JFAN-1001 Clinical Trial in NSCLC
Zhejiang Jianfeng Group Co., Ltd (SHA: 600668), a leading pharmaceutical company based in China, has...
MicroPort CardioFlow Medtech Completes Clinical Implantations of Second-Generation TAVI Device
MicroPort CardioFlow Medtech Co., Ltd (HKG: 2160), a spin-off of China-based MicroPort Scientific Corp (HKG:...
CSPC Pharmaceutical Gains NMPA Approval for Clinical Study of Bispecific Antibody NBL-028
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) has announced that it has received approval from...
Shanghai Henlius Initiates Global Phase III Study for HanSiZhuang in LS-SCLC
China’s Shanghai Henlius Biotech, Inc. (HKG: 2696) has announced the milestone of the first patient...
Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Cutia Therapeutics’ CU-20401 Completes Phase I Study for Obesity Treatment
China-based dermatology specialist Cutia Therapeutics (HKG: 2487) has announced the last subject out (LSO) in...
China Grand Pharma Initiates Phase III Trial for GPN00833 in Cataract Surgery Recovery
China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512; CGP) has announced a significant milestone...
Sihuan Pharmaceutical Gains NMPA Approval for Innovative Type 2 Diabetes Treatment
China’s Sihuan Pharmaceutical Holdings Group Ltd (HKG: 0460) has announced that it has received clinical...
Yiling Pharmaceutical Gains NMPA Approval for XY0206 in AML Trial
China-based Yiling Pharmaceutical Co., Ltd (SHE: 002603) has announced that it has received clinical trial...
Chengdu Kanghong Receives FDA Nod for Clinical Trial of Novel Depression Therapy KH607
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced that it has received...
Blue Sail Medical Enrolls First Patient in Study for Rapamycin-Coated Balloon Catheter
China’s Blue Sail Medical Co., Ltd (SHE: 002382) has announced a significant milestone with the...
Vcanbio Receives NMPA Approval for Clinical Study of VUM02 in SR-aGvHD Treatment
China-based biotechnology firm Vcanbio Cell & Gene Engineering Corp., Ltd (SHA: 600645) has announced that...
Beijing SL Pharmaceutical Gains NMPA Approval for Phase I Trial of MBT-1608 for Hepatitis C
China’s Beijing SL Pharmaceutical Co., Ltd (SHE: 002038) has announced that it has received approval...
Skyline Therapeutics Gains NMPA Approval for SKG0106 in Neovascular AMD Treatment
Skyline Therapeutics has announced that it has received clinical trial approval from the National Medical...
Boehringer Ingelheim’s Vitiligo Drug EI-001 Approved for Clinical Trials by NMPA
Germany’s Boehringer Ingelheim (BI) has announced that the National Medical Products Administration (NMPA) has approved...